Skip to main content
Clinical Trials/NCT06778538
NCT06778538CompletedNot Applicable

HPGD Overexpression Attenuates Tumorigenesis and EMT in Clear Cell Renal Cell Carcinoma by Upregulating SLCO2A1

Shang Panfeng1 site in 1 country40 target enrollmentStarted: July 1, 2024Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
40
Locations
1
Primary Endpoint
HPGD Expression Levels in clear cell renal cell carcinoma(ccRCC) Patients

Study Overview

Brief Summary

This study aims to investigate the role of HPGD in clear cell renal cell carcinoma (ccRCC). Specifically, it will focus on HPGD's impact on proliferation, epithelial-mesenchymal transition (EMT), and prognosis. The study will analyze gene expression data from clinical samples and use techniques like RT-qPCR, Western blotting, and immunohistochemistry to assess HPGD expression levels. Additionally, the research will explore the relationship between HPGD and patient survival outcomes. By elucidating HPGD's contribution to cancer progression, the study seeks to identify potential therapeutic targets for improving renal cancer treatment.

Detailed Description

This study is designed to comprehensively explore the role of 15-hydroxyprostaglandin dehydrogenase ( HPGD) in clear cell renal cell carcinoma development and progression. HPGD has been implicated in various cancers, with evidence suggesting its involvement in tumorigenesis, EMT, and poor prognosis. However, its specific function n clear cell renal cell carcinoma (ccRCC) is still unclear. This research will analyze clinical samples, including tumor tissues and normal adjacent tissues, to evaluate HPGD expression through a combination of advanced laboratory techniques such as quantitative real-time PCR (qRT-PCR), Western blotting, immunohistochemistry (IHC) and RNA sequencing.

Furthermore, HPGD-interacting proteins were predicted using STRING and TCGA data, followed by PCR, Western blot validation, and IHC. Mechanistically, HPGD positively correlated with the solute carrier organic anion transporter 2A1 (SLCO2A1), and SLCO2A1 knockdown partially attenuated the tumor-suppressive effects of HPGD overexpression..

This study underscores the tumor-suppressive role of HPGD in ccRCC, highlighting its capacity to hinder cell proliferation and EMT via its interaction with SLCO2A1. Targeting the HPGD-SLCO2A1 axis may offer a promising novel therapeutic approach for ccRCC management.

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Retrospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adults aged 18 years or older. Histologically confirmed diagnosis of clear cell renal cell carcinoma . Measurable disease as per RECIST criteria. Adequate organ function as defined by laboratory tests (e.g., liver, kidney, and hematologic function).
  • HPGD expression level determined via biopsy or previous analysis. Written informed consent provided.

Exclusion Criteria

  • History of other malignancies within the past 5 years, excluding non-melanoma skin cancer or in situ carcinoma.
  • Prior treatment with HPGD inhibitors or similar targeted therapies. Active or uncontrolled infections. Pregnant or breastfeeding women. Known autoimmune disorders or conditions requiring immunosuppressive therapy. Inability to comply with the study protocol or procedures.

Outcomes

Primary Outcomes

HPGD Expression Levels in clear cell renal cell carcinoma(ccRCC) Patients

Time Frame: 2024.1-2024.6

The primary outcome will measure the expression levels of HPGD in ccRCC tissues compared to adjacent normal tissues, and its correlation with clinical outcomes such as overall survival (OS) and progression-free survival (PFS).

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Shang Panfeng
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Shang Panfeng

Professor

Lanzhou University Second Hospital

Study Sites (1)

Loading locations...

Similar Trials